| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Key Financial ResultsCash, cash equivalents and depositsAs of March 31, 2024, the Company's cash and cash equivalents amoun...
The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on...
Inventiva's Lanifibranor improves cardiometabolic health in MASH/NASH patients. It lowers fasting glucose, reduces cardiova...
Inventiva (NASDAQ:IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies ...
Canaccord Genuity analyst Edward Nash maintains Inventiva (NASDAQ:IVA) with a Buy and raises the price target from $12 to $20.
HC Wainwright & Co. analyst Ed Arce reiterates Inventiva (NASDAQ:IVA) with a Buy and maintains $22 price target.
Key financial results for the full year of 2023As of December 31, 2023, the Company's cash and cash equivalents amounted to...
HC Wainwright & Co. analyst Ed Arce reiterates Inventiva (NASDAQ:IVA) with a Buy and maintains $22 price target.
LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lan...
